Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Blood Proteomics

ABSTRACT: Proteomic analysis of Blood from VTE and control patients from the Tromso study. Samples were analyzed by TMT based multiplexed quantitative proteomics

INSTRUMENT(S): Orbitrap Fusion

ORGANISM(S): Homo Sapiens (ncbitaxon:9606)

SUBMITTER: Kelly Frazer

PROVIDER: MSV000082489 | MassIVE | Fri Jun 22 09:25:00 BST 2018

SECONDARY ACCESSION(S): PXD010203

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNA Sequencing quantitatively profiles chemical long-term potentiation (LTP) induced gene transcription alteration

Project description:To identify proteins involved in activity dependent synaptic remodeling that are not caused by changes in mRNA levels we performed RNA-seq and TMT-based quantitative MS.

2021-02-20 | GSE110908 | GEO

Project description:Proteome of purified erythrocytes from blood samples from patients diagnosed with a PIEZO1-HX based on familial history, non-spherocytic chronic hemolysis, typical osmotic gradient ektacytometry and molecular testing and from healthy donors were analyzed by a label free quantification approach.

2023-03-11 | PXD031963 | Pride

Transcription profiling of human peripheral blood mononuclear cells treated with a CDK inhibitor

Project description:A genomics-based approach to identify pharmacodynamic biomarkers was used for a CDK (cyclin-dependent kinase) inhibitory drug. R547 is a potent CDK inhibitor with a potent anti-proliferative effect at pharmacologically relevant doses, and is currently in Phase I clinical trials. Utilizing preclinical data derived from microarray experiments, we identified pharmacodynamic biomarkers to test in blood samples from patients in clinical trials. These candidate biomarkers were chosen based on several criteria: relevance to the mechanism of action of R547, dose responsiveness in preclinical models, and measurable expression in blood samples. We identified 26 potential biomarkers of R547 action and tested their clinical validity in patient blood samples by quantitative real-time PCR analysis. Experiment Overall Design: 40 samples were initially run, 37 passed QC and were analyzed, samples were run in 6 independent replicates and were treated with either vehicle, R547 at the IC90, or R547 at 3 times the IC90. Additionally, untreated time zero samples were analyzed as a further control

2009-03-28 | E-GEOD-15389 | biostudies-arrayexpress

Proteomics analysis of novel serum protein biomarkers for the diagnosis of trastuzumab-resistant breast cancer

Project description:we executed a study of serum proteome differences between trastuzumab-resistance and trastuzumab-response HER2-positive breast cancer patients using an isobaric TMT label-based multiplexed quantitative proteomic method in combination with a comprehensive functional bioinformatics analysis. An LC-MS/MS-based multiple/selective reaction monitoring (MRM/SRM) quantification method was applied to validate several candidate biomarkers.

2022-04-01 | PXD016655 | Pride

Single cell RNAseq of ankylosing spondylitis lymphocytes from peripheral blood and synovial fluid

Project description:Single-cell transcriptome of >55,000 cells multiplexed into 4 channels obtained from peripheral blood and synovial fluid of two patients with HLA-B27+ ankylosing spondylitis,.

2021-10-18 | E-MTAB-10948 | biostudies-arrayexpress

GNPS UC_Severity_Multiomics MSV000082094

Project description:This study contains multiple omic data sets. Here we have data from a quantitative metaproteomic, metabolomic, and serum proteomic analysis of 40 patients with varying severity of Ulcerative Colitis. Fecal samples were analyzed through proteomics using TMT MS3 quantitation. Fecal samples were analyzed for metabolomics through LCMS2 on a Bruker Maxis qTOF. Samples were selected based on clinical endoscopic scores.

2018-02-23 | MSV000082094 | GNPS

Analysis of differential expression profiles of Long noncoding RNA in peripheral blood of patients with active rheumatoid arthritis

Project description:we studied the expression profile of lncRNA in peripheral blood of patients with active RA LncRNA and mRNA expression in peripheral blood from two activity RA patients and two healthy donors were analyzed with microarray profiling. peripheral blood of five active RA patients and five healthy control members were collected. Quantitative real-time PCR was further used to screen and verify the expression of lncRNA to verify the expression of the selected lncRNA; perform bioinformatics analysis to study the potential function of the differentially expressed genes, construct a receiver operating characteristic (ROC) curve to evaluate the clinical diagnostic value of the identified lncRNA, and use correlation analysis to explore the relationship between aberrantly expressed lncRNA that may have diagnostic value and clinical indicators.

2020-06-10 | GSE134087 | GEO

Comparison of microRNA expression with whole blood between ER positive breast cancer patients and normal controls

Project description:Background MicroRNA expression is frequently dysregulated in cancer and it could be used potentially as a disease classifier and a prognostic tool in cancer. It has been reported that the cancer associated specific microRNAs were stably detected in blood. The objective of this study was to discover a panel of circulating microRNAs as potential ER+/HER2- breast cancer biomarkers. Methods We compared levels of circulating microRNAs in blood samples from 11 ER+/HER2- advanced breast cancer patients with age-matched 5 control subjects by using microarray-based expression profiling. We validated the level of microRNAs by real-time quantitative polymerase cycle reaction (RT-qPCR) in 40 control subjects, 180 early breast cancer patients (EBC), and 52 metastatic breast cancer patients (MBC). Then, we assessed the association between the levels of microRNA and clinical outcomes of ER+/HER2- metastatic breast cancer. Background MicroRNA expression is frequently dysregulated in cancer and it could be used potentially as a disease classifier and a prognostic tool in cancer. It has been reported that the cancer associated specific microRNAs were stably detected in blood. The objective of this study was to discover a panel of circulating microRNAs as potential ER+/HER2- breast cancer biomarkers. Methods We compared levels of circulating microRNAs in blood samples from 11 ER+/HER2- advanced breast cancer patients with age-matched 5 control subjects by using microarray-based expression profiling. We validated the level of microRNAs by real-time quantitative polymerase cycle reaction (RT-qPCR) in 40 control subjects, 180 early breast cancer patients (EBC), and 52 metastatic breast cancer patients (MBC). Then, we assessed the association between the levels of microRNA and clinical outcomes of ER+/HER2- metastatic breast cancer.

2013-12-12 | GSE53179 | GEO

scRNAseq of blood and CSF CD4+ T cells from MS patients and controls

Project description:To study the regulation of candidate genes from our study in human cells, we analyzed CD4+ T cells from blood and CSF of MA patients and age and sex matched idiopathic intracranial hypertension controls We analyzed 40845 cells in control blood, 807 cells in control CSF, 29749 cells in MS blood and 15768 cells in MS CSF

2023-08-01 | GSE232343 | GEO

Comparison of microRNA expression with whole blood between ER positive breast cancer patients and normal controls

2013-12-12 | E-GEOD-53179 | biostudies-arrayexpress